Rate this item
(0 votes)

Elena Fingerut, Ph.D.

By Super User 24 November, 2015 1445

Director of Quality Control and Manager of Research and Development and Immunomonitoring. Dr. Fingerut has been with the Company since 2006 and has been responsible for developing our GMP quality control documentation and procedures for in-coming, in-process and release of immunotherapy drug products. She has also developed and established methods for collection, shipping and testing of immunological samples from patients for evaluation of the clinical efficiency of the products. Elena has a Ph.D. from the Hebrew University, Jerusalem in Animal Science with a focus on Molecular Biology and Immunology. Elena has published several articles and was co-author in two patents in the field of vaccine development.

Share

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more